Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002

JAMA

Volumn 291, Issue 1, 2004, Pages 54-62

  Stafford, Randall S ^a   Furberg, Curt D ^b   Finkelstein, Stan N ^c   Cockburn, Iain M ^d   Alehegn, Tseday ^a   Ma, Jun ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; DOXAZOSIN MESYLATE; GENERIC DRUG; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; PRAZOSIN; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMPETITION; DRUG COST; DRUG EFFECT; DRUG MARKETING; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; STATISTICAL SIGNIFICANCE;

EID: 0345967847     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.1.54     Document Type: Article

References (35)

1. Dunn DR. Dissemination of the published results of an important clinical trial: an analysis of the citing literature. Bull Med Libr Assoc. 1981;69:301-306.
2. Collins R, Julian D. British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. Br Heart J. 1991;66:250-255.
3. Friedman L, Wenger NK, Knatterud GL. Impact of the Coronary Drug Project findings on clinical practice. Control Clin Trials. 1983;4:513-522.
4. Reiffel JA, Cook JR. Physician attitudes toward the use of type IC antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol. 1990;66:1262-1264.
5. Lacy CR, Barone JA, Suh DC, et al. Impact of presentation of research results on likelihood of prescribing medications to patients with left ventricular dysfunction. Am J Cardiol. 2001;87:203-207.
6. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E, The SAVE Investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241-247.
7. Zoorab R, Wormuth C, McCarthy-Larzelere M. Asthma: knowledge and practice patterns of Louisiana family physicians. J La State Med Soc. 2002;154:136-140.
8. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension. 2000;36:600-603.
9. Hesdorffer DC, Ghajar J, Iacono L. Predictors of compliance with the evidence-based guidelines for traumatic brain injury care: a survey of United States trauma centers. J Trauma. 2002;52:1202-1209.
10. Hogben M, St Lawrence JS, Kasprzyk D, et al. Sexually transmitted disease screening by United States obstetricians and gynecologists. Obstet Gynecol. 2002;100:801-807.
11. Libby EN, Garcia DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med. 2002;162:1893-1896.
12. McCracken GH Jr. Clinical practice guidelines for the diagnosis and treatment of respiratory tract infections. Am J Manag Care. 2001;7(suppl 6):S183-S191.
13. Mottur-Pilson C, Snow V, Bartlett K. Physician explanations for failing to comply with "best practices." Eff Clin Pract. 2001;4:207-213.
14. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? a framework for improvement. JAMA. 1999;282:1458-1465.
15. Cabana MD. Barriersto guideline adherence: based on a presentation by Michael Cabana, MD. Am J Manag Care. 1998;4:S741-S744; discussion S745-S748.
16. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15:478-483.
17. Guldal D, Semin S. The influences of drug companies' advertising programs on physicians. Int J Health Serv. 2000;30:585-595.
18. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380.
19. Pressel SL, Davis BR, Wright JT, et al. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials. 2001;22:29-41.
20. NHLBI stops part of study-high blood pressure drug performs no better than standard treatment [news release]. Bethesda, Md: National Institutes of Health; March 8, 2000.
21. Messerli FH, Grossman E. Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Curr Hypertens Rep. 2000;2:241-242.
22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
24. Furberg CD. A new era in hypertension research: discussing the findings of ALLHAT. Curr Control Trials Cardiovasc Med. 2001;2:249-250.
25. Messerli FH. Doxazosin and congestive heart failure. J Am Coll Cardiol. 2001;38:1295-1296.
26. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure the fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) Arch Intern Med. 1993;153:154-183.
27. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. Arch Intern Med. 1997;157:2413-2446.
28. Conover WJ. Practical Nonparametric Statistics. New York, NY: John Wiley & Sons Inc; 1980:94-101.
29. IMS HEALTH. National Prescription Audit Plus, Therapeutic Category Report Documentation: Confidence Limit Tables-Prescribed and Dispensed Drugs, 1996-2001. Plymouth Meeting, Pa: IMS HEALTH; 2001.
30. IMS HEALTH. National Disease and Therapeutic Index, Diagnosis Report Documentation: Estimated Sampling Error for Diagnosis Visits, 1996-2002. Plymouth Meeting, Pa: IMS HEALTH; 2002.
31. Hurwitz MA, Caves RE. Persuasion or information: promotion and the shares of brand name and generic pharmaceuticals. J Law Econ. 1998;31:299-320.
32. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. Econ Manag Strategy. 1997;6:77-90.
33. National Institute for Health Care Management Research and Educational Foundation. Factors Affecting Growth of Prescription Drug Expenditures: Report by the National Institute for Health Care Management Research and Educational Foundation. Washington, DC: National Institute for Health Care Management Research and Educational Foundation; 1999.
34. National Institute for Health Care Management Research and Educational Foundation. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs: Report by the National Institute for Health Care Management Research and Educational Foundation. Washington, DC: National Institute for Health Care Management Research and Educational Foundation; 2002.
35. Majumdar SR, Inui TS, Gurwitz JH, Gillman MW, McLaughlin TJ, Soumerai SB. Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction. J Gen Intern Med. 2001;16:351-359.